Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

96.71 -0.10 (-0.10%)
Streaming Delayed Price Updated: 1:54 PM EST, Dec 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,929,620
Open 96.40
Bid (Size) 96.69 (2)
Ask (Size) 96.70 (1)
Prev. Close 96.81
Today's Range 96.22 - 97.05
52wk Range 62.41 - 105.69
Shares Outstanding N/A
Dividend Yield 1.83%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 10 Years
Via Benzinga
Why Viking Therapeutics Was Crushing It This Week
Nowadays, it's good to be a developer of next-generation weight loss drugs. 
Via The Motley Fool

Performance

YTD
+41.22%
+41.22%
1 Month
-4.90%
-4.90%
3 Month
-1.00%
-1.00%
6 Month
+21.30%
+21.30%
1 Year
+54.44%
+54.44%

More News

Read More
Could Eli Lilly Beat Novo Nordisk in the Billion-Dollar Weight Loss Market?
Via The Motley Fool
Zoetis Stock A Good Companion For Your Portfolio? Shares Rising
Via Investor's Business Daily
JNJ CEO Signals No Rush Into Weight-Loss Drug Realm, Emphasizes Different Priorities
Via Benzinga
Obesity Drugs: Greater Weight Loss Linked to Prolonged Use of Novo Nordisk's Wegovy
Via Benzinga
Everyone Is Talking About This Stock. Is It a Good Long-Term Option?
Via The Motley Fool
Simply Good Foods: Winner in the Ozempic Weight-Loss Trend
Via MarketBeat
Jim Cramer Highlights 'Transformational' Impact Of Weight Loss Drugs Like Ozempic: Focus Now On 'Potential Winners' From The Same Narrative
Via Benzinga
Roche, Pfizer Race To Find Next Ozempic As Pharma Giants Hustle To Join Obesity Treatment Market
Via Benzinga
Roche Stock Rises On $3.1 Billion Deal For Obesity Drugmaker
Via Investor's Business Daily
Ozempic vs. Mounjaro:: Battle of the bulge
Via MarketBeat
Exposures Product Safety
Roche Joins Bandwagon To Challenge Novo Nordisk, Eli Lilly For Weight Loss Drugs
Via Benzinga
1 Stock-Split Stock to Buy Hand Over Fist in December, and 1 to Avoid Like the Plague
Via The Motley Fool
3 No-Brainer Growth Stocks to Buy in December
Via The Motley Fool
Pfizer Tumbles After Abandoning Weight-Loss Pill
Via Talk Markets
An Important History Lesson for Gene-Editing Investors
Via The Motley Fool
Is Eli Lilly a Better Stock to Buy and Hold Over the Next 10 Years Than Novo Nordisk?
Via The Motley Fool
Advocacy for Wegovy: Denmark Signals Cost-Sharing Talks While Novo Spent Millions On Medical Community For Drug Promotion
Via Benzinga
Weight Loss Drugs And Associated Suicidal Thoughts - European Drug Regulator Seeks Clarifications From Drug Makers
Via Benzinga
Weight Loss Drugs - Novo Nordisk A Primary Beneficiary In Obesity Space Currently Controlled By Two Players, Says Analyst
Via Benzinga
Pfizer Halts Development Of Twice-Daily Weight-Loss Drug; PFE Stock Slides
Via Investor's Business Daily
Dow Jones Hits 2023 High, Nasdaq Slips; Tesla Cybertruck, Salesforce In Focus: Weekly Review
Via Investor's Business Daily
Topics Economy Stocks
Exposures Interest Rates US Equities
Pfizer’s Stock Is Down 44% YTD As Woes Continue
Via Talk Markets
Will Novo Nordisk Be a Trillion-Dollar Stock by 2030?
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.